Skip to main content

Table 4 Comparison between 4 weeks pre- and 4 weeks post-TMS as regards clinical data of migraine, MIDAS, and serum levels of neurokinin A in group B (migraine with aura)

From: Repetitive transcranial magnetic stimulation as a prophylactic treatment in migraine

  With aura Test value P value
Pre-TMS, no. = 10 Post-TMS, no. = 10
Neurokinin A serum level Mean ± SD 23.64 ± 1.87 13.09 ± 3.58 − 2.803 0.005
Range 20.46–26.45 9.69–22.55
No. of headache attacks (days per month) Median (IQR) 16.50 (15.00–20.00) 3.00 (2.00–6.00) − 2.807ǂ 0.005
Range 12.00–21.00 0.00–20.00
Duration of individual attack (hours) Median (IQR) 15.00 (12.25–25.50) .25 (0.13–0.69) − 2.803ǂ 0.005
Range 4.75–28.50 0.00–13.00
No. of pills (per month) Median (IQR) 19.50 (12.00–26.00) 0.00 (0.00–0.00) − 2.666ǂ 0.008
Range 0.00–36.00 0.00–20.00
Pain intensity Median (IQR) 7.50 (7.25–7.75) .75 (0.50–2.00) − 2.812ǂ 0.005
Range 6.50–8.50 0.00–7.00
MIDAS score Median (IQR) 35.00 (22.00–46.00) 2.00 (0.00–4.00) − 2.705ǂ 0.007
Range 17.00–49.00 0.00–47.00
  1. P value > 0.05, non-significant (NS); P value < 0.05, significant (S); P value < 0.001, highly significant (HS)
  2. Paired t test
  3. ǂWilcoxon’s rank test